First Patient Dosed In Kronos Bio's KB-0742, In An Expansion Cohort Focused On Platinum-Resistant High-Grade Serous Ovarian Cancer

— KB-0742 cleared 80mg four-days-on, three-days-off dosing schedule in dose escalation —

 

— Company expects to provide an efficacy update on this expansion cohort in 1H 2025 —

SAN MATEO, Calif. and CAMBRIDGE, Mass., July 23, 2024 (GLOBE NEWSWIRE) --  Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule. This expansion cohort is enrolling platinum-resistant patients with high-grade serous ovarian cancer (HGSOC), a tumor type which is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and deficiencies in homologous recombination (HRD+).